Hims & Hers Health (NYSE:HIMS) Insider Sells $100,957.37 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 3,461 shares of the stock in a transaction on Wednesday, September 30th. The shares were sold at an average price of $29.17, for a total value of $100,957.37. Following the completion of the transaction, the insider owned 300,809 shares in the company, valued at $8,774,598.53. The trade was a 1.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Soleil Boughton also recently made the following trade(s):

• On Wednesday, September 16th, Soleil Boughton sold 6,236 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.86, for a total value of $173,734.96.
• On Wednesday, September 2nd, Soleil Boughton sold 3,458 shares of Hims & Hers Health stock. The shares were sold at an average price of $28.33, for a total value of $97,965.14.
• On Wednesday, August 19th, Soleil Boughton sold 25,111 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.55, for a total value of $691,808.05.

Hims & Hers Health Trading Down 1.2%

HIMS stock traded down $0.34 during midday trading on Friday, reaching $28.96. The stock had a trading volume of 10,052,970 shares, compared to its average volume of 23,671,156. The business has a fifty day simple moving average of $29.27 and a two-hundred day simple moving average of $28.24. The company has a quick ratio of 0.87, a current ratio of 0.93 and a debt-to-equity ratio of 4.21. The firm has a market cap of $6.76 billion, a price-to-earnings ratio of -45.97 and a beta of 2.44. Hims & Hers Health, Inc. has a twelve month low of $13.74 and a twelve month high of $65.30.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.32). Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%.The firm had revenue of $753.21 million for the quarter, compared to the consensus estimate of $698.90 million. During the same period in the prior year, the firm posted $0.17 earnings per share. The business’s revenue for the quarter was up 38.2% compared to the same quarter last year. As a group, research analysts expect that Hims & Hers Health, Inc. will post -0.16 EPS for the current fiscal year.

More Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers and Hims Australia appointed chief medical officers in the United Kingdom and Australia, strengthening local clinical leadership as the company expands internationally. Hims & Hers Names Chief Medical Officers in the UK and Australia
• Neutral Sentiment: Multiple law firms, including Rosen, Kaplan Fox, SBS and Robbins Geller, reminded investors that purchasers of HIMS securities between August 4, 2025, and July 29, 2026, may seek appointment as lead plaintiff by November 2, 2026. These announcements are largely procedural and do not represent new claims by themselves. Rosen Securities Class Action Deadline Notice
• Negative Sentiment: Hims & Hers is the subject of a securities class action alleging that the company and certain executives made material misstatements or omissions, including regarding allegedly deceptive and unlawful privacy practices. The case reportedly follows an FTC complaint alleging serious business misconduct. The allegations have not been proven, but the litigation could create legal costs, potential damages and additional regulatory or reputational pressure. Hims & Hers Securities Class Action Following FTC Complaint
• Negative Sentiment: Recent reports noted that HIMS declined during a session in which the overall market rose, suggesting investor sentiment remains pressured by the FTC-related controversy and lawsuit headlines. Continued coverage from numerous plaintiff firms may keep volatility elevated while investors await developments in the case. HIMS Stock Slides as Market Rises

Institutional Trading of Hims & Hers Health

Large investors have recently made changes to their positions in the company. QRG Capital Management Inc. acquired a new position in Hims & Hers Health in the second quarter valued at about $248,000. Envestnet Portfolio Solutions Inc. increased its holdings in shares of Hims & Hers Health by 46.9% in the second quarter. Envestnet Portfolio Solutions Inc. now owns 32,469 shares of the company’s stock worth $1,126,000 after acquiring an additional 10,366 shares in the last quarter. Bienville Capital Management LLC acquired a new stake in shares of Hims & Hers Health during the second quarter worth about $27,242,000. Engineers Gate Manager LP bought a new position in shares of Hims & Hers Health during the 2nd quarter valued at about $232,000. Finally, Integrated Wealth Concepts LLC acquired a new position in shares of Hims & Hers Health in the 2nd quarter valued at approximately $147,000. Institutional investors own 63.52% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Truist Financial raised their price objective on shares of Hims & Hers Health from $27.00 to $32.00 and gave the company a “hold” rating in a research note on Monday, August 24th. Weiss Ratings reiterated a “sell (d)” rating on shares of Hims & Hers Health in a research report on Friday, August 7th. Canaccord Genuity Group increased their price target on Hims & Hers Health from $32.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday, July 1st. TD Cowen raised their price target on Hims & Hers Health from $25.00 to $30.00 and gave the stock a “hold” rating in a research report on Tuesday, August 11th. Finally, Bank of America lifted their price objective on Hims & Hers Health from $30.00 to $32.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 11th. Three research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $32.43.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a direct-to-consumer telehealth company that provides access to personalized healthcare through its online platforms, Hims and Hers. The company connects consumers with licensed healthcare professionals for virtual consultations, treatment plans and prescription medications where appropriate.

Its services address a range of common health and wellness needs, including sexual health, hair loss, skincare, mental health, weight management and primary care. Hims & Hers offers branded and generic treatments, over-the-counter products, supplements and personal-care products, with services designed for both men and women.

The company was founded in 2016, launched the Hims brand in 2017 and introduced the Hers brand in 2018.